Company Alnylam Pharmaceuticals, Inc. Börse Stuttgart
Equities
DUL
US02043Q1076
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
227.2 EUR | -1.65% | +59.42% | +31.55% |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Ribonucleic Acid Interference Therapeutics
100.0
%
| 1,037 | 100.0 % | 1,828 | 100.0 % | +76.23% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
69.8
%
| 616 | 59.4 % | 1,276 | 69.8 % | +107.21% |
Europe
21.8
%
| 315 | 30.4 % | 399 | 21.8 % | +26.83% |
Rest of the World
8.4
%
| 107 | 10.3 % | 153 | 8.4 % | +43.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Chief Tech/Sci/R&D Officer | - | 17-07-31 | |
Kevin Fitzgerald
CTO | Chief Tech/Sci/R&D Officer | 56 | 04-12-31 |
James Bilotta
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
Pushkal Garg
CTO | Chief Tech/Sci/R&D Officer | 56 | 14-10-28 |
Joshua Brodsky
IRO | Public Communications Contact | - | 21-01-31 |
Investor Relations Contact | 43 | 15-08-31 | |
Eric Green
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Amy Schulman
CHM | Chairman | 63 | 14-06-30 |
Phillip Sharp
FOU | Founder | 79 | 02-06-13 |
Peter Kellogg
BRD | Director/Board Member | 67 | 23-03-06 |
Michael Bonney
BRD | Director/Board Member | 65 | 14-12-16 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 12-04-22 |
Colleen Reitan
BRD | Director/Board Member | 64 | 18-05-31 |
Chief Executive Officer | 61 | 16-09-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 126,491,778 | 125,961,653 ( 99.58 %) | 0 | 99.58 % |
Company contact information
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street Henri A. Termeer Square
02142, Cambridge
+617 551 8200
http://www.alnylam.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.21% | 39.1B | |
-7.82% | 38.76B | |
+12.71% | 25.9B | |
-13.75% | 25.8B | |
+45.95% | 14.06B | |
+39.98% | 13.12B | |
-6.50% | 11.32B | |
-12.26% | 10.68B | |
-7.38% | 9.12B |
- Stock Market
- Equities
- ALNY Stock
- DUL Stock
- Company Alnylam Pharmaceuticals, Inc.